Our Pricing

Your Complete Guide to Mounjaro Dose Increases

Understanding the mounjaro dose increase schedule uk prescribers follow is essential for safe, effective weight loss. At Cured Pharmacy, our UK clinical team guides you through each dose progression from the initial 2.5mg maintenance dose to the maximum 15mg strength, ensuring you achieve optimal results whilst minimising side effects.

The Standard Mounjaro Dose Increase Schedule UK

Mounjaro (tirzepatide) follows a structured dose escalation protocol licensed by the MHRA, starting at 2.5mg once weekly for four weeks [1]. This initial maintenance dose allows your body to adapt to the medication's dual GIP/GLP-1 receptor agonist mechanism before progressing to higher strengths.

The standard UK titration schedule progresses through five dose levels: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Each dose is maintained for at least four weeks before escalation, allowing your UK prescriber to assess tolerability and weight loss response [1]. Clinical trials demonstrated that this gradual approach significantly reduces gastrointestinal side effects compared to rapid dose increases.

At Cured Pharmacy, Mounjaro is available from £135.00 with transparent pricing across all dose strengths. Your prescriber will determine your optimal progression schedule during your free online consultation, which takes under three minutes to complete.

When Should You Increase Your Mounjaro Dose?

Dose progression timing depends on two key factors: tolerability and weight loss response. UK prescribers typically recommend increasing your dose after completing four weeks on your current strength, provided you're not experiencing significant side effects [2].

If you're achieving consistent weight loss of 1-2% of body weight per week and tolerating your current dose well, your prescriber may approve progression to the next strength. However, if you're experiencing persistent nausea, vomiting, or diarrhoea, remaining on your current dose for an additional four weeks is often recommended [2].

Some patients achieve their weight loss goals on lower doses and don't require escalation to 15mg. In the SURPASS-1 trial, participants on 10mg tirzepatide achieved an average 19.5% body weight reduction over 40 weeks, demonstrating that intermediate doses can produce substantial results [1].

Signs You're Ready to Progress

Your UK prescriber will look for specific indicators that you're ready for dose escalation: minimal gastrointestinal side effects for at least two weeks, consistent adherence to your weekly injection schedule, and either continued weight loss or a plateau lasting more than three weeks. Appetite suppression typically diminishes slightly before a dose increase is needed, which is a normal sign your body has adapted to your current strength.

Mounjaro Dose Progression: 2.5mg to 15mg Explained

The 2.5mg starting dose serves as an initiation phase rather than a therapeutic dose. Most patients experience mild appetite reduction but limited weight loss during this first month. This dose primes your GIP and GLP-1 receptors for the therapeutic doses that follow [1].

Progression to 5mg typically produces noticeable appetite suppression and weight loss averaging 2-3% of body weight over four weeks. The 7.5mg and 10mg doses represent the therapeutic sweet spot for many patients, with clinical trials showing average weight reductions of 15-20% at these strengths [1][3].

The 12.5mg and 15mg doses are reserved for patients requiring maximum efficacy. In SURPASS-3, the 15mg dose produced an average 22.5% body weight reduction over 72 weeks, significantly outperforming comparator treatments [3]. However, not all patients require or tolerate these higher strengths.

Dose-Dependent Effects

Higher Mounjaro doses produce greater weight loss but also increase the likelihood of gastrointestinal side effects. Approximately 20-30% of patients on 15mg experience nausea compared to 12-15% on 5mg, though symptoms typically resolve within 2-4 weeks [2]. Your UK prescriber will balance efficacy against tolerability when determining your optimal maintenance dose.

How Long Should You Stay on Each Mounjaro Dose?

The minimum recommended duration on each dose is four weeks, allowing sufficient time for your body to adapt and for weight loss effects to manifest [1]. However, many UK prescribers recommend staying on each dose for 6-8 weeks if you're achieving consistent weight loss and tolerating the medication well.

Remaining on a dose longer than four weeks isn't a setback—it's often a strategic decision. If you're losing 1-2% of body weight weekly on 7.5mg, there's no clinical benefit to rushing to 10mg. The goal is sustainable weight loss with minimal side effects, not rapid dose escalation [2].

Some patients reach their target weight before completing the full dose progression. If you've achieved your goal on 10mg, your prescriber may recommend maintaining that dose rather than escalating to 12.5mg or 15mg. Weight maintenance typically requires ongoing treatment, though some patients successfully transition to lower maintenance doses.

Managing Side Effects During Dose Increases

Gastrointestinal side effects—particularly nausea, diarrhoea, and constipation—are most common during the first 2-3 weeks after a dose increase [2]. These symptoms reflect tirzepatide's mechanism of action, which slows gastric emptying and increases satiety signals.

To minimise side effects during dose escalation, eat smaller, more frequent meals rather than large portions, avoid high-fat and spicy foods for the first week after increasing your dose, and stay well-hydrated throughout the day. If nausea becomes severe or persistent beyond three weeks, contact your UK prescriber—you may benefit from remaining on your current dose for an additional month [2].

Serious side effects requiring immediate medical attention include severe abdominal pain, persistent vomiting preventing fluid intake, signs of pancreatitis, or allergic reactions. These are rare, occurring in less than 2% of patients, but require prompt evaluation [1][2].

When to Delay Dose Escalation

Your UK prescriber may recommend delaying your next dose increase if you're experiencing ongoing nausea or vomiting, have had difficulty maintaining adequate hydration, experienced a recent illness or infection, or haven't yet achieved consistent weight loss on your current dose. Delaying escalation by 2-4 weeks is a common, clinically appropriate decision that doesn't compromise long-term outcomes.

Mounjaro Dose Increases vs Other Weight Loss Treatments

Unlike Wegovy (semaglutide), which follows a four-dose escalation schedule from 0.25mg to 2.4mg over 16-20 weeks, Mounjaro's six-dose progression allows for more granular titration and potentially better tolerability [4]. The additional intermediate doses (7.5mg and 12.5mg) give prescribers greater flexibility in finding your optimal therapeutic dose.

Saxenda (liraglutide) requires daily injections with dose escalation over five weeks, whereas Mounjaro's once-weekly administration and slower titration schedule typically produce better adherence rates. In comparative trials, tirzepatide demonstrated superior weight loss outcomes across all dose levels compared to semaglutide 1mg, with the 15mg dose producing nearly double the weight reduction [3][4].

At Cured Pharmacy, we offer comprehensive weight loss treatment options including Mounjaro from £135.00 Wegovy, Saxenda, and oral alternatives like Orlistat. Your UK prescriber will recommend the most appropriate treatment and dosing schedule based on your medical history, weight loss goals, and tolerance for injectable medications. All treatments require completion of a free online consultation with our UK-registered clinical team.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/14298
3. Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.